tradingkey.logo
tradingkey.logo
Search

Edwards Lifesciences Corp

EW
Add to Watchlist
83.800USD
-0.570-0.68%
Close 07-23 16:00ETQuotes delayed by 15 min
48.35BMarket Cap
44.50P/E TTM

Earnings Forecast

Currency: USD Updated: 2026-07-23
Previous score
7.88
Change
0
The current earnings forecast score of Edwards Lifesciences Corp is 7.88, ranking 118 out of 200 in the Healthcare Equipment & Supplies industry. The average price target is 95.50, with a high of 105.00 and a low of 72.00.

Analyst Rating

Based on 32 analysts
Buy
Current Rating
97.266
Target Price
+15.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

88
Total
4
Median
7
Average
Company name
Ratings
Analysts
Edwards Lifesciences Corp
EW
32
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Thermo Fisher Scientific Inc
TMO
30
Veeva Systems Inc
VEEV
30
Danaher Corp
DHR
26
1
2
3
...
18

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

FAQs

What is Edwards Lifesciences Corp's expected revenue for the next quarter?

Edwards Lifesciences Corp's expected revenue is 1.69B.

What is Edwards Lifesciences Corp's price target?

Analysts forecast that Edwards Lifesciences Corp's price target is USD 95.50, with the highest forecast at USD 105.00 and the lowest forecast at USD 72.00.

How have Edwards Lifesciences CorpEW's recent earnings per share performed?

The market expectation was USD 0.42, while Edwards Lifesciences CorpEW's earnings per share (EPS) for the previous quarter was USD 0.66. EPS for the next quarter is expected at USD 0.74.

What is the analyst rating for Edwards Lifesciences Corp?

Based on the ratings of Edwards Lifesciences Corp's stock from 32 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.